4.7 Article

Accelerated lipid catabolism and autophagy are cancer survival mechanisms under inhibited glutaminolysis

期刊

CANCER LETTERS
卷 430, 期 -, 页码 133-147

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2018.05.017

关键词

Cancer metabolism; Glutaminolysis inhibition; Cancer survival mechanisms; Beta-oxidation; Autophagy

类别

资金

  1. QNRF grant [NPRP8-061-3-011]
  2. 'Biomedical Research Program' funds at Weill Cornell Medicine in Qatar - Qatar Foundation

向作者/读者索取更多资源

Suppressing glutaminolysis does not always induce cancer cell death in glutamine dependent tumors because cells may switch to alternative energy sources. To reveal compensatory metabolic pathways, we investigated the metabolome-wide cellular response to inhibited glutaminolysis in cancer cells. Glutaminolysis inhibition with C.968 suppressed cell proliferation but was insufficient to induce cancer cell death. We found that lipid catabolism was activated as a compensation for glutaminolysis inhibition. Accelerated lipid catabolism, together with oxidative stress induced by glutaminolysis inhibition, triggered autophagy. Simultaneously inhibiting glutaminolysis and either beta oxidation with trimetazidine or autophagy with chloroquine both induced cancer cell death. Here we identified metabolic escape mechanisms contributing to cancer cell survival under treatment and we suggest potentially translational strategy for combined cancer therapy, given that chloroquine is an FDA approved drug. Our findings are first to show efficiency of combined inhibition of glutaminolysis and beta oxidation as potential anti-cancer strategy as well as add to the evidence that combined inhibition of glutaminolysis and autophagy may be effective in glutamine-addicted cancers.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Chemistry, Multidisciplinary

Applications of polydopaminic nanomaterials in mucosal drug delivery

Takwa Bedhiafi, Sourour Idoudi, Areej Ali Alhams, Queenie Fernandes, Heba Iqbal, Renuka Basineni, Shahab Uddin, Said Dermime, Maysaloun Merhi, Nashiru Billa

Summary: Polydopamine (PDA) is a biopolymer with unique physicochemical properties and has various applications in drug delivery, biosensing, imaging, and cancer therapy. Recent research has discovered the potential of PDA as a coating material for mucosal drug delivery, but there is limited information on this application. This review presents the properties of PDA and its biomedical applications, with a focus on its role as a coating material for nanoparticulate carriers in mucosal drug delivery. The challenges and possibilities of translating this technology to clinical studies are also discussed.

JOURNAL OF CONTROLLED RELEASE (2023)

Review Biochemistry & Molecular Biology

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

Karama Makni Maalej, Maysaloun Merhi, Varghese P. Inchakalody, Sarra Mestiri, Majid Alam, Cristina Maccalli, Honar Cherif, Shahab Uddin, Martin Steinhoff, Francesco M. Marincola, Said Dermime

Summary: In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has shown efficacy in treating hematological malignancies, but its value in solid tumors remains inconclusive. The limitations of CAR-T cell therapy in solid tumors include limited tumor trafficking and infiltration, an immunosuppressive tumor microenvironment, and adverse events. CAR-NK and CAR-M cells have been introduced as alternative immunotherapies for solid tumors, with potential advantages such as no HLA compatibility requirement and limited toxicity for CAR-NK cells, and capabilities of phagocytosis, tumor-antigen presentation, and broad tumor infiltration for CAR-M cells. Prospective solutions, such as combination therapies, could enhance the efficacy of CAR-cell immunotherapy.

MOLECULAR CANCER (2023)

Article Biochemistry & Molecular Biology

Studies on anti-colon cancer potential of nanoformulations of curcumin and succinylated curcumin in mannosylated chitosan

Sourour Idoudi, Takwa Bedhiafi, Fairooz Sahir, Yousef Hijji, Shahab Uddin, Maysaloun Merhi, Said Dermime, Nashiru Billa

Summary: This study evaluated the anti-cancer activity of curcumin nanoparticles (CUR-NPs) and succinylated curcumin nanoparticles (CUR.SA-NPs) on colon cancer cell lines. The nanoparticles showed dose and time-dependent cytotoxicity, inducing apoptosis through activation of Caspase signaling. Based on their promising attributes and in vitro results, further investigation into the role of these nanoparticle formulations in CRC management is warranted.

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2023)

Article Immunology

Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression

Afsheen Raza, Reyad Mohsen, Aladdin Kanbour, Abdul Rehman Zar Gul, Anite Philip, Suma Vijayakumar, Shereena Hydrose, Kirti S. Prabhu, Aisha Khamis Al-Suwaidi, Varghese Philipose Inchakalody, Maysaloun Merhi, Dina Abo M. El-Ella, Melissa Annrose Tauro, Shayista Akbar, Issam Al-Bozom, Wafa Abualainin, Rajaa Al-Abdulla, Shaza Abu Sirriya, Suparna Hassnad, Shahab Uddin, Mohamed Izham Mohamed Ibrahim, Ussama Al Homsi, Said Demime

Summary: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related morbidity and mortality worldwide. Immune checkpoint inhibitors (ICIs) have significantly changed the treatment outcomes in NSCLC, but only a small percentage of patients respond to this therapy. This study aimed to identify pre-treatment soluble immune molecules as surrogate biomarkers for tissue PD-L1 status and predictors of response to anti-PD-1/PD-L1 therapy in NSCLC patients. The analysis of soluble biomarkers showed significant up/down regulation of immune inhibitory checkpoint markers in patients with higher tissue PD-L1 expression. Moreover, certain soluble immune molecules were found to be associated with better progression-free survival and predictive of response to therapy.

FRONTIERS IN IMMUNOLOGY (2023)

Article Medicine, General & Internal

Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib

Sara Voelkel, Thomas S. Tarawneh, Laura Sacher, Aditya M. Bhagwat, Ihab Karim, Hildegard I. D. Mack, Thomas Wiesmann, Bjoern Beutel, Joachim Hoyer, Christian Keller, Harald Renz, Andreas Burchert, Andreas Neubauer, Johannes Graumann, Chrysanthi Skevaki, Elisabeth K. M. Mack

Summary: This study found that COVID-19-ARDS patients who received Ruxolitinib treatment showed significant changes in the serum proteome, involving biological processes such as T-cell response, humoral immune response, and complement activation. In addition, Ruxolitinib regulates the NRF2 pathway and SARS-CoV-2 signaling.

FRONTIERS IN MEDICINE (2023)

Review Medicine, Research & Experimental

Integrative toxicogenomics: Advancing precision medicine and toxicology through artificial intelligence and OMICs technology

Ajay Vikram Singh, Vaisali Chandrasekar, Namuna Paudel, Peter Laux, Andreas Luch, Donato Gemmati, Veronica Tisato, Kirti S. Prabhu, Shahab Uddin, Sarada Prasad Dakua

Summary: More information about genetic makeup, drug response, multi-omics response, and genomic response is now available, leading to personalized treatment. Non-animal testing and computational toxicogenomics are becoming integral parts of risk assessment. Artificial intelligence (AI) has the potential to analyze patient data, predict treatment outcomes, and expedite data processing in personalized medicine and toxicogenomics. This article explores the current trends, future perspectives, challenges, and limitations in personalized medicine, toxicogenomics, and AI.

BIOMEDICINE & PHARMACOTHERAPY (2023)

Review Oncology

Exosome nanovesicles as potential biomarkers and immune checkpoint signaling modulators in lung cancer microenvironment: recent advances and emerging concepts

Naushad Ahmad Khan, Mohammad Asim, Kabir H. Biswas, Amani N. Alansari, Harman Saman, Mohammad Zahid Sarwar, Kudaibergen Osmonaliev, Shahab Uddin

Summary: Lung cancer is a leading cause of cancer-related deaths worldwide. Tumor-derived exosomes (TEXs) play a crucial role in the progression of lung cancer by modulating the immune response and promoting key processes such as metastasis, epithelial-mesenchymal transition, angiogenesis, and immunosuppression. Understanding the role of TEXs in lung cancer tumorigenesis and their response to immunotherapies is important for developing non-invasive biomarkers and improving lung cancer therapy.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2023)

Review Pathology

Multiple myeloma and its rare paraneoplastic manifestations simmering under the surface

Sehrish Sarwar Baloch, Saqib Raza Khan, Muhammad Tariq, Abdul Wasio, Ayesha Arshad Ali, Mehwish Shahzadi, Munira Moosajee, Shaheena Anwar, Afsheen Raza, Shahab Uddin

Summary: Paraneoplastic syndromes are complex clinical manifestations caused by hormones, cytokines, peptides or antibodies produced by malignant cells in the underlying malignancy, affecting multiple organ systems. Multiple Myeloma (MM), accounting for 10-15% of hematological malignancies and 1-2% of all malignancies, is associated with atypical clinical and laboratory paraneoplastic manifestations. Understanding these manifestations is important for differential diagnosis in uncertain cases.

PATHOLOGY RESEARCH AND PRACTICE (2023)

Article Oncology

Epigenetic programing of cancer stemness by transcription factors-non-coding RNAs interactions

Reem Khaled M. E. Alsayed, Khalid Sultan A. M. Sheikhan, Majid Ali Alam, Jorg Buddenkotte, Martin Steinhoff, Shahab Uddin, Aamir Ahmad

Summary: Cancer 'stemness' is crucial for the existence and characteristics of cancer cells. Transcription factors such as NF-KB and STAT-3 play a significant role in cancer stemness and are potential targets for cancer therapy. The study of non-coding RNAs has revealed their interactions with these transcription factors, offering insights into the regulatory mechanisms of cancer stemness and potential therapeutic opportunities.

SEMINARS IN CANCER BIOLOGY (2023)

Review Cell & Tissue Engineering

Unveiling the Therapeutic Potential of Non-Coding RNAs in Stroke-Induced Tissue Regeneration

Arshi Waseem, Abdul Quaiyoom Khan, Mohsin Ali Khan, Rehan Khan, Shahab Uddin, Johannes Boltze, Syed Shadab Raza

Summary: Stroke is a leading cause of death and disability worldwide, but effective treatments are limited. Abnormal expression of various non-coding RNAs (ncRNAs) has been found after stroke, affecting processes such as neurogenesis, angiogenesis, apoptosis, and autophagy. Understanding the roles and mechanisms of ncRNAs holds promise for future stroke treatments, as they can modify the impact and progression of stroke on a molecular level. Exploring the functions and underlying mechanisms of ncRNAs after stroke may reveal new therapeutic targets and improve diagnostics for stroke.

STEM CELLS (2023)

Article Cell Biology

Identification of PCSK9-like human gene knockouts using metabolomics, proteomics, and whole-genome sequencing in a consanguineous population

Aziz Belkadi, Gaurav Thareja, Fatemeh Abbaszadeh, Ramin Badii, Eric Fauman, Karsten Qatar Genome Program Res Consortium, Karsten Suhre

Summary: Natural human knockouts of genes associated with desirable outcomes can lead to the discovery of new drug targets and treatments. This study combined whole-genome sequencing with proteomics and metabolomics to evaluate the power of this approach for finding genes of clinical and pharmaceutical interest. A rare PCSK9 variant with low circulating levels was identified in a homozygous carrier from the Qatar Biobank, highlighting the potential of consanguineous populations for drug discovery.

CELL GENOMICS (2023)

Article Cell Biology

Role of HMGB1 and its associated signaling pathways in human malignancies

Sourour Idoudi, Takwa Bedhiafi, Shona Pedersen, Mohamed Elahtem, Izzaldin Alremawi, Sabah Akhtar, Said Dermime, Maysaloun Merhi, Shahab Uddin

Summary: This review focuses on the role of HMGB1 in human malignancies and the signaling pathways associated with it. It also discusses the potential of HMGB1 as a target/biomarker for cancer therapy, as well as the therapeutic strategies used to target HMGB1.

CELLULAR SIGNALLING (2023)

Meeting Abstract Biochemistry & Molecular Biology

Multi-ancestry meta-analysis of genome-wide association studies of lung function and variant-to-genemapping undercover hundreds of novel implicated genes and loci

Abril Izquierdo, Nick Shrine, Jing Chen, Anna Guyatt, Richard Packer, Chiara Batini, Karsten Suhre, Alfred Pozarickij, Robin G. Walters, Stephanie London, Andrew Morris, Louise Wain, Ian P. Hall, Martin D. Tobin

EUROPEAN JOURNAL OF HUMAN GENETICS (2023)

Article Pharmacology & Pharmacy

Shrinking the battlefield in cancer therapy: Nanotechnology against cancer stem cells

Queenie Fernandes, Lubna Therachiyil, Abdul Q. Khan, Takwa Bedhiafi, Hesham M. Korashy, Ajaz A. Bhat, Shahab Uddin

Summary: Cancer is a major cause of death worldwide and current treatments have limited efficacy. Nanotechnology offers innovative solutions by leveraging the unique properties of nanomaterials, improving drug efficiency, reducing side effects, and targeting cancer stem cells. However, there are still challenges in obtaining clinical approval for nano-drugs.

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2023)

Review Oncology

The role of LncRNA MCM3AP-AS1 in human cancer

Shirin Azizidoost, Farhoodeh Ghaedrahmati, Mohadeseh Sheykhi-Sabzehpoush, Shahab Uddin, Mehri Ghafourian, Abdolah Mousavi Salehi, Mona Keivan, Maryam Cheraghzadeh, Zahra Nazeri, Maryam Farzaneh, Seyed Esmaeil Khoshnam

Summary: MCM3AP-AS1, a long noncoding RNA, is implicated in the progression of several types of cancers by targeting various signaling pathways and microRNAs associated with cancer development.

CLINICAL & TRANSLATIONAL ONCOLOGY (2023)

Review Oncology

Small extracellular vesicles: Non-negligible vesicles in tumor progression, diagnosis, and therapy

Xinru Zhou, Yin Jia, Chuanbin Mao, Shanrong Liu

Summary: Small extracellular vesicles (sEVs), such as exosomes, have emerged as crucial targets for liquid biopsy and promising drug delivery vehicles in tumor progression. They can serve as biomarkers for tumor diagnosis and as drug carriers for cancer treatment.

CANCER LETTERS (2024)

Article Oncology

HMGB1 in the interplay between autophagy and apoptosis in cancer

Ruochan Chen, Ju Zhu, Xiao Zhong, Jie Li, Rui Kang, Daolin Tang

Summary: The interplay between autophagy and apoptosis plays a crucial role in tumorigenesis and cancer therapy, with HMGB1 serving as a key regulator in these processes.

CANCER LETTERS (2024)

Article Oncology

Epigenetic inhibition of CTCF by HN1 promotes dedifferentiation and stemness of anaplastic thyroid cancer

Zongfu Pan, Xixuan Lu, Tong Xu, Jinming Chen, Lisha Bao, Ying Li, Yingying Gong, Yulu Che, Xiaozhou Zou, Zhuo Tan, Ping Huang, Minghua Ge

Summary: This study uncovered the emerging role of HN1 in promoting dedifferentiation of anaplastic thyroid cancer (ATC) cells. HN1 negatively regulated the thyroid differentiation markers and had an inhibitory effect on the transcriptional activation of CTCF, thereby influencing the chromatin accessibility of thyroid differentiation genes.

CANCER LETTERS (2024)

Article Oncology

Autophagy machinery in glioblastoma: The prospect of cell death crosstalk and drug resistance with bioinformatics analysis

Yi Qin, Shengjun Xiong, Jun Ren, Gautam Sethi

Summary: Autophagy plays an important regulatory role in glioblastoma, and its dysregulation can lead to drug resistance and radioresistance. It also affects stem cell characteristics, overall growth, and metastasis. Therefore, autophagy is a promising target for glioblastoma therapy.

CANCER LETTERS (2024)

Article Oncology

Elevated 2-oxoglutarate antagonizes DNA damage responses in cholangiocarcinoma chemotherapy through regulating aspartate beta-hydroxylase

Katsuya Nagaoka, Xuewei Bai, Dan Liu, Kevin Cao, Joud Mulla, Chengcheng Ji, Hongze Chen, Muhammad Azhar Nisar, Amalia Bay, William Mueller, Grace Hildebrand, Jin-Song Gao, Shaolei Lu, Hiroko Setoyama, Yasuhito Tanaka, Jack R. Wands, Chiung-Kuei Huang

Summary: This study found that serum 2-OG levels in cholangiocarcinoma patients are associated with the effectiveness of chemotherapy. Patients with progressive disease showed significantly higher levels of serum 2-OG compared to stable disease and partial response patients. The study also revealed that overexpression of ASPH mimics the effects of 2-OG, and knockdown of ASPH improves chemotherapy. Targeting ASPH enhances the effects of chemotherapy by modulating ATM and ATR, two key regulators of DDRs.

CANCER LETTERS (2024)